SYNERGENE ACTIVE INGREDIENTS PVT.LTD.
Systematic Approach For Innovation

   + 91-40-23700794 / 23700994
   marketing@synergeneapi.com
ACHIEVEMENTS
Achievements and Future Plans

ISO 9001: 2015, ISO 14001:2015 and OHSAS 18001:2007 certifications for Unit I and Unit II

WHO-GMP certification for Unit I

CEP for Fluconazole in May 2014.(R0-CEP 2011-338 –REV00 dated 27.05.2014).

Best Supplier Award from Dr. Reddy’s Laboratories Ltd in 2014

EU Written Confirmation for 5 products namely Fluconazole, Terbinafine Hydrochloride, Escitalopram Oxalate, Losartan Potassium and Dapoxetine Hydrochloride in September 2014

USFDA Inspection and E.I.R. for Unit II in December 2016.

 

Business Partner Excellence Award from Dr. Reddy’s Laboratories Ltd in 2016 “For innovative development and supply of critical molecules within stipulated time-frame and for turning around our facility in short span resulting in successful compliance of regulatory audit.”

CEP for Terbinafine Hydrochloride in March 2017.( RO-CEP 2015-235-Rev 00 dated 30.03.2017).

Process Patents for Escitalopram Oxalate Patent No. IN283492, S (+) Dapoxetine Hydrochloride Patent No. IN287150 and Luliconazole Patent No. IN314738

WHO-GMP certification for Unit II

EU Written Confirmation for Luliconazole, Sumatriptan Succinate, Voriconazole and Flupirtine Maleate in March 2020